Showing results (61-70 of 250) with videos related to
Sort By:
Pageof 25
International Journal of Hematology|November 15, 2002
The myelodysplastic syndromes: morphology, risk assessment, and clinical management (2002)John M Bennett, Peter A Kouides, Stephen J FormanClinical Lymphoma, Myeloma & Leukemia|March 7, 2020
Defining Acute Myeloid Leukemia Ontogeny in Older PatientsMegan Melody, Andrew Kuykendall, David Sallman, et al.Leukemia & Lymphoma|June 11, 2021
What is the optimal time to initiate hypomethylating agents (HMAs) in higher risk myelodysplastic syndromes (MDSs)?Rami Komrokji, Najla Al Ali, Eric Padron, et al.Clinical Lymphoma, Myeloma & Leukemia|June 27, 2022
CPX-351 Yields Similar Response and Survival Outcome in Younger and Older Patients With Secondary Acute Myeloid LeukemiaDasom Lee, Akriti G Jain, Yehuda Deutsch, et al.Leukemia Research Reports|February 25, 2015
"Preleukemic or smoldering" chronic myelogenous leukemia (CML):BCR-ABL1 positive: A brief case reportJohn M Bennett, Kevin G Dsouza, Mehul Patel, et al.The Journal of the Kentucky Medical Association|March 4, 2008
Targeting influenza in KentuckyJohn M Bennett, Baretta Casey, Michael E Samuels, et al.Critical Reviews in Oncology/Hematology|August 12, 2009
WITHDRAWN: Enhancing geriatric oncology training to care for elders: A clinical initiative with long-term follow-upJohn M Bennett, William J Hall, Deepak Sahasrabudhe, et al.Clinical Lymphoma, Myeloma & Leukemia|August 9, 2023
Utilization of Serial Next-Generation Sequencing Among Patients Receiving CPX-351 for Newly Diagnosed Acute Myeloid LeukemiaAkriti G Jain, Somedeb Ball, Luis E Aguirre, et al.Oncotarget|February 11, 2017
Outcome of patients treated for myelodysplastic syndromes without deletion 5q after failure of lenalidomide therapyThomas Prebet, Andrea Toma, Thomas Cluzeau, et al.The Oncologist|November 10, 2017
Azacitidine in Lower-Risk Myelodysplastic Syndromes: A Meta-Analysis of Data from Prospective StudiesRami Komrokji, Arlene S Swern, David Grinblatt, et al.Pageof 25